{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:09:35Z","timestamp":1789754975414,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.cardfail.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T02:13:19Z","timestamp":1603505599000},"page":"233-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-2466","authenticated-orcid":false,"given":"Daniel","family":"Burkhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7528","authenticated-orcid":false,"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Staedtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Udelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2020.10.007_bib0001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.09.011","article-title":"Congestion in acute heart failure syndromes: an essential target of evaluation and treatment","volume":"119","author":"Gheorghiade","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0002","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","article-title":"Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure","volume":"258","author":"Rubio-Gracia","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1753944717718717","article-title":"A perspective on diuretic resistance in chronic congestive heart failure","volume":"11","author":"Shah","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828","article-title":"Decongestive therapy and renal function in acute heart failure: time for a new approach?","volume":"7","author":"Goldsmith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0008","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0009","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1172\/JCI112034","article-title":"Effect of arginine vasopressin on renal medullary blood flow. A videomicroscopic study in the rat","volume":"76","author":"Zimmerhackl","year":"1985","journal-title":". J Clin Invest"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cellsig.2015.07.021","article-title":"Arginine vasopressin receptor signaling and functional outcomes in heart failure","volume":"28","author":"Wasilewski","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0012","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0013","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0014","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11897-013-0175-3","article-title":"Vasopressin receptor antagonists: from pivotal trials to current practice","volume":"11","author":"Kalra","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0017","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/FJC.0000000000000677","article-title":"Vascular protection and decongestion without renin-angiotensin-aldosterone system stimulation mediated by a novel dual-acting vasopressin V1a\/V2 receptor antagonist","volume":"74","author":"Kolkhof","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0021","article-title":"Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a\/V2 receptor antagonist in experimental heart failure","author":"Mondritzki","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0022","series-title":"A novel balanced dual vasopressin V1a\/V2 receptor antagonist for treatment of congestive heart failure: results from a first-in-man study","first-page":"11","author":"Pimenta","year":"2017"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0023","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.107.690768","article-title":"Patterns of weight change preceding hospitalization for heart failure","volume":"116","author":"Chaudhry","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2016.09.012","article-title":"Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial","volume":"5","author":"Ambrosy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0025","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0026","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/01.HYP.37.6.1429","article-title":"Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men","volume":"37","author":"Kelly","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","article-title":"Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial","volume":"34","author":"Ambrosy","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0028","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0029","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0031","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/ehf2.12783","article-title":"Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF)","volume":"7","author":"Ng","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0032","first-page":"R193","article-title":"Control of renal medullary blood flow by vasopressin V1 and V2 receptors","volume":"269","author":"Nakanishi","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ejhf.1050","article-title":"Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion","volume":"20","author":"Van Aelst","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0034","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0035","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0036","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1536\/ihj.18-671","article-title":"A prospective, multicenter, post-marketing surveillance study to evaluate the safety and effectiveness of tolvaptan in patients with reduced, preserved, and mid-range ejection fraction heart failure","volume":"60","author":"Kinugawa","year":"2019","journal-title":"Int Heart J"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0037","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2020.10.007_bib0038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrendo.2010.229","article-title":"Vaptans for the treatment of hyponatremia","volume":"7","author":"Robertson","year":"2011","journal-title":"Nat Rev Endocrinol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916420314834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916420314834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:44:53Z","timestamp":1761029093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916420314834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1071916420314834"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2020.10.007","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}